title: Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer.
abstract: This retrospective analysis evaluated the mechanism of bevacizumab plus chemotherapy (BV+CT) for preventing brain metastasis derived from lung cancer. From the total of 159 patients with advanced non-small cell lung cancer (NSCLC), 110 received BV+CT and 49 received CT. After medication, both groups had 15 patients with brain metastases (14 vs 31%, P < 0.05). With BV+CT treatment, 40 patients (33.89%) survived, whereas only 11 patients (18.64%) survived with CT treatment. The outcome for the BV+CT group was significantly better than that for the CT group only for vascular endothelial growth factor (VEGF)-positive patients. A post-treatment with BV+CT was significantly reduced than with CT only for patients with high carbonic anhydrase-9 (CA9) expression. This retrospective analysis provides supportive evidence that BV+CT can significantly reduce the incidence of brain metastasis in patients with advanced NSCLC compared with CT alone. Vascular endothelial growth factor -positive patients may benefit more from BV treatment and the outcomes with BV may be related to CA9 expression.
authors.affiliation: a Department of Oncology , The First Affiliated Hospital of Chinese PLA General Hospital , Beijing 100048 , China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Fu
authors.affiliation: a Department of Oncology , The First Affiliated Hospital of Chinese PLA General Hospital , Beijing 100048 , China.
authors.forename: Jia
authors.initials: J
authors.lastname: Hu
authors.affiliation: a Department of Oncology , The First Affiliated Hospital of Chinese PLA General Hospital , Beijing 100048 , China.
authors.forename: Nan
authors.initials: N
authors.lastname: Du
authors.affiliation: b Cancer Center , Chinese PLA General Hospital , Beijing 100853 , China.
authors.forename: Shunchang
authors.initials: S
authors.lastname: Jiao
authors.affiliation: b Cancer Center , Chinese PLA General Hospital , Beijing 100853 , China.
authors.forename: Fang
authors.initials: F
authors.lastname: Li
authors.affiliation: a Department of Oncology , The First Affiliated Hospital of Chinese PLA General Hospital , Beijing 100048 , China.
authors.forename: Xiaosong
authors.initials: X
authors.lastname: Li
authors.affiliation: a Department of Oncology , The First Affiliated Hospital of Chinese PLA General Hospital , Beijing 100048 , China.
authors.forename: Junxun
authors.initials: J
authors.lastname: Ma
authors.affiliation: a Department of Oncology , The First Affiliated Hospital of Chinese PLA General Hospital , Beijing 100048 , China.
authors.forename: Hui
authors.initials: H
authors.lastname: Zhao
authors.affiliation: a Department of Oncology , The First Affiliated Hospital of Chinese PLA General Hospital , Beijing 100048 , China.
authors.forename: Huanrong
authors.initials: H
authors.lastname: Kang
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000068258:Bevacizumab / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000401:mortality / Q000517:prevention & control* / Q000556:secondary; D000071231:Carbonic Anhydrase IX / Q000097:blood; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis / Q000096:biosynthesis
chemical_list: D000951:Antigens, Neoplasm; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX
keywords: Bevacizumab; Brain metastasis; NSCLC